Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
Cardiol Therapeutics has raised $10.7M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Cardiol Therapeutics's investors include Raymond James, AlbaCore Capital, Canaccord Genuity Group, Echelon Wealth Partners.
Cardiol Therapeutics is headquartered in Oakville, Canada.
Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
Cardiol Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardiol Therapeutics — Funding & Investors." VCBacked, January 16, 2026, https://www.vcbacked.co/company/cardiol-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Cardiol Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cardiol-therapeutics
{{cite web |title=Cardiol Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cardiol-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated